News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
648,005 Results
Type
Article (51136)
Company Profile (431)
Press Release (596423)
Multimedia
Podcasts (161)
Webinars (20)
Section
Business (162496)
Career Advice (3107)
Deals (30004)
Drug Delivery (127)
Drug Development (80711)
Employer Resources (177)
FDA (15471)
Job Trends (13209)
News (294155)
Policy (28911)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2757)
Academic (1)
Accelerated approval (33)
Adcomms (36)
Allergies (145)
Alliances (43553)
ALS (178)
Alzheimer's disease (1741)
Antibody-drug conjugate (ADC) (343)
Approvals (15677)
Artificial intelligence (546)
Autoimmune disease (170)
Automation (35)
Bankruptcy (292)
Best Places to Work (10879)
BIOSECURE Act (19)
Biosimilars (188)
Biotechnology (307)
Bladder cancer (160)
Brain cancer (64)
Breast cancer (659)
Cancer (4965)
Cardiovascular disease (437)
Career advice (2641)
Career pathing (40)
CAR-T (312)
CDC (45)
Celiac Disease (2)
Cell therapy (842)
Cervical cancer (36)
Clinical research (68774)
Collaboration (1778)
Company closure (5)
Compensation (1111)
Complete response letters (71)
COVID-19 (2658)
CRISPR (98)
C-suite (838)
Cystic fibrosis (154)
Data (6309)
Decentralized trials (2)
Denatured (50)
Depression (145)
Diabetes (525)
Diagnostics (5907)
Digital health (46)
Diversity (10)
Diversity, equity & inclusion (44)
Drug discovery (274)
Drug pricing (200)
Drug shortages (34)
Duchenne muscular dystrophy (247)
Earnings (64134)
Editorial (66)
Employer branding (22)
Employer resources (159)
Events (111549)
Executive appointments (929)
FDA (18548)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1509)
Gene editing (214)
Generative AI (50)
Gene therapy (686)
GLP-1 (1089)
Government (4623)
Grass and pollen (7)
Guidances (351)
Healthcare (18254)
HIV (64)
Huntington's disease (48)
IgA nephropathy (85)
Immunology and inflammation (284)
Immuno-oncology (62)
Indications (107)
Infectious disease (2921)
Inflammatory bowel disease (203)
Inflation Reduction Act (17)
Influenza (108)
Intellectual property (249)
Interviews (606)
IPO (14620)
IRA (54)
Job creations (2719)
Job search strategy (2137)
JPM (70)
Kidney cancer (17)
Labor market (82)
Layoffs (538)
Leadership (40)
Legal (5994)
Liver cancer (89)
Longevity (15)
Lung cancer (664)
Lymphoma (382)
Machine learning (41)
Management (63)
Manufacturing (812)
MASH (174)
Medical device (12060)
Medtech (12109)
Mergers & acquisitions (16484)
Metabolic disorders (1403)
Multiple sclerosis (161)
NASH (23)
Neurodegenerative disease (350)
Neuropsychiatric disorders (101)
Neuroscience (3044)
Neurotech (1)
NextGen: Class of 2026 (6275)
Non-profit (4520)
Now hiring (49)
Obesity (694)
Opinion (327)
Ovarian cancer (169)
Pain (212)
Pancreatic cancer (223)
Parkinson's disease (294)
Partnered (33)
Patents (489)
Patient recruitment (503)
Peanut (57)
People (49486)
Pharmaceutical (77)
Pharmacy benefit managers (29)
Phase 1 (21654)
Phase 2 (30393)
Phase 3 (22576)
Pipeline (5228)
Policy (310)
Postmarket research (2389)
Preclinical (9184)
Press Release (66)
Prostate cancer (252)
Psychedelics (56)
Radiopharmaceuticals (300)
Rare diseases (931)
Real estate (4971)
Recruiting (75)
Regulatory (22803)
Reports (39)
Research institute (2482)
Resumes & cover letters (496)
Rett syndrome (28)
RNA editing (21)
RSV (75)
Schizophrenia (158)
Series A (251)
Series B (198)
Service/supplier (10)
Sickle cell disease (104)
Special edition (27)
Spinal muscular atrophy (168)
Sponsored (46)
Startups (3275)
State (2)
Stomach cancer (19)
Supply chain (104)
Tariffs (86)
The Weekly (110)
Vaccines (982)
Venture capital (96)
Weight loss (471)
Women's health (81)
Worklife (22)
Date
Today (142)
Last 7 days (563)
Last 30 days (2064)
Last 365 days (30126)
2026 (3313)
2025 (30374)
2024 (34849)
2023 (38957)
2022 (49046)
2021 (53222)
2020 (50940)
2019 (43879)
2018 (33187)
2017 (30703)
2016 (30197)
2015 (34732)
2014 (27078)
2013 (22138)
2012 (23189)
2011 (23752)
2010 (21738)
Location
Africa (864)
Alabama (83)
Alaska (6)
Arizona (241)
Arkansas (14)
Asia (38173)
Australia (6742)
California (10968)
Canada (3175)
China (1145)
Colorado (455)
Connecticut (462)
Delaware (328)
Europe (89165)
Florida (1608)
Georgia (341)
Hawaii (3)
Idaho (53)
Illinois (836)
India (67)
Indiana (488)
Iowa (20)
Japan (427)
Kansas (119)
Kentucky (36)
Louisiana (27)
Maine (57)
Maryland (1288)
Massachusetts (8212)
Michigan (301)
Minnesota (586)
Mississippi (4)
Missouri (129)
Montana (31)
Nebraska (22)
Nevada (107)
New Hampshire (76)
New Jersey (2957)
New Mexico (31)
New York (2909)
North Carolina (1458)
North Dakota (9)
Northern California (5338)
Ohio (321)
Oklahoma (21)
Oregon (40)
Pennsylvania (2212)
Puerto Rico (20)
Rhode Island (45)
South America (1140)
South Carolina (61)
Southern California (4272)
Tennessee (139)
Texas (1668)
United States (39074)
Utah (299)
Vermont (1)
Virginia (256)
Washington D.C. (73)
Washington State (931)
West Virginia (4)
Wisconsin (107)
Wyoming (1)
648,005 Results for "the obesity society".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity
Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.
February 4, 2026
·
2 min read
·
Tristan Manalac
Earnings
Amgen Wants MariTide To Change Obesity Paradigm With Longer Dosing Periods
Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its investigational obesity drug MariTide will continue to provide competitive weight loss even at monthly or longer schedules.
February 4, 2026
·
2 min read
·
Tristan Manalac
Earnings
Roche Plans To Go Toe-to-Toe With Novo, Lilly in Obesity
Roche aims to become a “top three player” in obesity, Teresa Graham, CEO of the group’s Pharma unit, said Thursday during a presentation of the company’s full-year 2025 earnings.
January 29, 2026
·
2 min read
Manufacturing
Eli Lilly Commits $3.5B To Build Injectable Obesity Drug Plant in PA
The facility, which is part of Lilly’s $50 billion reshoring drive, will make obesity drugs such as tirzepatide and retatrutide when it starts operations in 2031.
February 2, 2026
·
2 min read
·
Nick Paul Taylor
Obesity
Lilly Doubles Down With Nimbus, Paying $55M for Preclinical Obesity Drug
Eli Lilly kicked off a pivotal 2026 campaign with a multi-year collaboration with current partner Nimbus Therapeutics worth a potential $1.3 billion for a preclinical obesity therapeutic. The deal follows a 2022 partnership struck by the companies to target the AMPK protein in cardiometabolic diseases.
January 6, 2026
·
2 min read
·
Heather McKenzie
Podcast
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as Health Secretary Robert F. Kennedy’s anti-vaccine policies and rhetoric continues; and embattled gene therapy maker Sarepta announces new data in Duchenne muscular dystrophy.
January 28, 2026
·
1 min read
·
Heather McKenzie
Manufacturing
Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge
Genentech, a member of the Roche Group, plans to open the facility in 2029 to ramp up capacity to make obesity candidates, including the dual GLP-1/GIP receptor agonist CT-388.
January 21, 2026
·
2 min read
·
Nick Paul Taylor
Business
JPM26: Novo Refocuses on Diabetes and Obesity Amid Push To Expand GLP-1 Market
After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, obesity or overweight.
January 14, 2026
·
3 min read
·
Nick Paul Taylor
Events
JPM26 Day 1: Obesity Front-and-Center, Q4 Sales Beats
Obesity took center stage on the first day of the 2026 J.P. Morgan Healthcare Conference, with industry frontrunners Eli Lilly and Novo Nordisk providing supply chain, regulatory and pricing updates.
January 13, 2026
·
3 min read
·
Tristan Manalac
Obesity
Zealand Freezes Mid-Stage Obesity Asset To Focus on More Differentiated Drugs
The decision to pause dapiglutide will help Zealand focus investment into assets that have “the greatest potential for clinical differentiation” in obesity.
November 13, 2025
·
2 min read
·
Tristan Manalac
1 of 64,801
Next
